«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:

21

期数:

2020年06期

页码:

832-834

栏目:

论　著

出版日期:

2020-06-28

文章信息/Info

Title:

Effect of quadruple therapy on helicobacter pylori clearance rate in patients with chronic gastritis

作者:

李志鹏

高唐县人民医院，山东 高唐 252800

Author(s):

LIZhi-peng

Gaotang People’Hospital,Gaotang,Shandong222800,China Correspondingauthor：LIZhi-peng，E-mail:rongyao1949@163.com

关键词:

慢性胃炎; 幽门螺杆菌; 清除率; 四联疗法

Keywords:

Chronic gastritis;  Helicobacter pylori;  Clearance rate;  Quadruple therapy

分类号:

R573.3

DOI:

-

摘要:

目的 探讨四联疗法对幽门螺杆菌（Hp）感染所致慢性胃炎患者Hp清除率的影响。方法 选择2018年 4月至2019年4月高唐县人民医院收治的Hp感染所致慢性胃炎患者90例作为研究对象，随机分为两组，其中对 照组43例给奥美拉唑、克拉霉素以及阿莫西林治疗，观察组47例给予奥美拉唑、克拉霉素以及阿莫西林、橼酸 铋钾治疗。观察两组治疗14 d后的疗效、Hp清除率、治疗前后肠道菌群变化情况及不良反应发生情况。结果 观察组治疗总有效率（95.74%）、Hp清除率（93.62%）高于对照组（79.07%、72.09%），差异有统计学意义 （P<0.05）；两组患者治疗前的双歧杆菌、乳酸杆菌、肠球菌及大肠杆菌含量比较，差异均无统计学意义（P> 0.05）；观察组治疗后的各菌群含量均高于对照组（P<0.05）；与对照组相比（13.95%），观察组不良反应发生率 （6.38%）略低，但差异无统计学意义（P>0.05）。结论 四联疗法应用于Hp感染所致慢性胃炎患者中的疗效较 佳，能够提高Hp的清除率，并纠正肠道菌群失调且安全有效。

Abstract:

Objective To investigate the effect of quadruple therapy on helicobacter pylori（Hp）clear-ance rate in patients with chronic gastritis caused by Hp infection. Methods Totally90 cases of pa-tients with chronic gastritis caused by Hp infection who admitted in Gaotang People’Hospital from April2018 to April 2019 were randomly divided into two groups. Control group（43 cases）was treat-ed with omeprazole, clarithromycin and amoxicillin, and observation group（47 cases）was treated with omeprazole, clarithromycin, amoxicillin and bismuth potassium citrate. The efficacy after treatment for 14 days, Hp clearance rate, changes of intestinal flora before and after treatment, and adverse reac-tions in two groups were observed. Results The total effective rate and Hp clearance rate of obser-vation group were significantly higher than those of control group（95.74% vs.79.07%,93.62% vs. 72.00%）（P<0.05）. There were no statistical difference in the contents of bifidobacterium, lactobacil-lus, enterococcus and escherichia coli between two groups before treatment （P>0.05）. The contents of the aboved flora in observation group were higher than those in control group after treatment（P< 0.05）. The incidence of adverse reactions in observation group （6.38%）was slightly lower than that in control group （13.95%）, but the difference was not statistically significant（P>0.05）. Conclusion Quadruple therapy in patients with chronic gastritis caused by Hp infection has better efficacy, can in-crease Hp clearance rate and correct alteration of intestinal flora, which is safe and effective.

参考文献/References:

[1] 刘辉,何春艳.铋剂四联疗法对慢性胃炎患者临床症状及胃泌素 的影响[J].贵州医药,2018,42(1):54-57. [2] 汪楠,王垂杰,李玉锋.中药联合“四联疗法”治疗Hp阳性慢性胃 炎疗效观察[J].中国中西医结合杂志,2017,32(4):406-409. [3] Holleczek B, Sch?ttker B, Brenner H. Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer:results from the prospective population-based ESTHER cohort study [J]. Int J Cancer, 2019,46 (10):2773-2783. [4] 杨佳卉,梁雨,罗培培,等.荆花胃康联合三联或四联疗法与四联 疗法对比治疗幽门螺杆菌相关慢性胃炎或消化性溃疡有效性和 安全性的Meta分析[J].中国全科医学,2019,22(17):2091-2098. [5] 葛均波,陈灏珠.内科学[M].9版.北京:人民卫生出版社,2018: 355-356. [6] 朱新影,杜娟,赵文娟,等.不同疗程复方嗜酸乳杆菌片联合四联 疗法清除幽门螺杆菌的疗效分析[J].中国微生态学杂志,2017,29 (8):909-912. [7] 杨佳卉,梁雨,罗培培,等.荆花胃康联合三联或四联疗法与四联 疗法对比治疗幽门螺杆菌相关慢性胃炎或消化性溃疡有效性和 安全性的Meta分析[J].中国全科医学,2019,22(17):2091-2098. [8] Huang J, Zagai U, Hallmans G,et al. Helicobacter pylo-ri infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort [J]. Int J Cancer, 2017,140(8):1727. [9] 李海娥,魏小果,罗舒丹,等.酪酸梭菌活菌胶囊联合标准四联疗 法清除幽门螺杆菌感染的临床研究[J].中国微生态学杂志,2019, 31(2):61-63. [10] 刘春,方之洪.四联疗法与传统三联疗法治疗小儿胃炎合并消化 性溃疡的临床疗效对比研究[J].现代消化及介入诊疗,2019,24 (3):268-270. [11] 刘晓川,王静,郭敏,等.四联疗法后延长质子泵抑制剂和铋剂治 疗对胃炎患者幽门螺杆菌清除效果的影[J].临床和实验医学杂 志,2019,18(10):1064-1068.

备注/Memo

备注/Memo:

作者简介：李志鹏，大学本科，主治医师，研究方向：消化内科疾病诊疗、消化内镜下诊疗 通信作者：李志鹏，E-mail：rongyao1949@163.com

常用功能

更新日期/Last Update: 2020-06-28